Bravura Solutions Limited logo

Bravura Solutions Limited (BVS)

Market Closed
CXA CXA
- Market Cap
- P/E Ratio
0% Div Yield
60,177 Volume
- Eps
Earnings results expected in 4 days

Summary

BVS closed Thursday lower, a decrease of 2.18% from Wednesday's close, completing a monthly decrease of -1.32%. Over the past 12 months, BVS stock gained 6.16%.
BVS is not paying dividends to its shareholders.
The last earnings report, released on Mar 10, 2025, exceeded the consensus estimates by 0.06%. On average, the company has surpassed earnings expectations by 0.07%, based on the last three reports. The next scheduled earnings report is due on May 05, 2025.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track BVS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025.

Globenewswire | 2 days ago
4 Healthcare Stocks to Buy as the Sector Faces Government Heat

4 Healthcare Stocks to Buy as the Sector Faces Government Heat

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Zacks | 1 week ago
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks | 1 month ago

Bravura Solutions Limited Dividends

BVS is not paying dividends to its shareholders.

Bravura Solutions Limited Earnings

5 May 2025 (4 Days) Date
-
Cons. EPS
-
EPS
10 Mar 2025 Date
0.09
Cons. EPS
0.15
EPS
5 Nov 2024 Date
0.03
Cons. EPS
0.06
EPS
6 Aug 2024 Date
0.07
Cons. EPS
0.19
EPS
7 May 2024 Date
-
Cons. EPS
0.07
EPS
BVS is not paying dividends to its shareholders.
5 May 2025 (4 Days) Date
-
Cons. EPS
-
EPS
10 Mar 2025 Date
0.09
Cons. EPS
0.15
EPS
5 Nov 2024 Date
0.03
Cons. EPS
0.06
EPS
6 Aug 2024 Date
0.07
Cons. EPS
0.19
EPS
7 May 2024 Date
-
Cons. EPS
0.07
EPS

Bravura Solutions Limited (BVS) FAQ

On which exchange is it traded?

Bravura Solutions Limited is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is BVS.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 05, 2025.

Has Bravura Solutions Limited ever had a stock split?

No, there has never been a stock split.

Bravura Solutions Limited Profile

Medical Devices Industry
Healthcare Sector
Mr. Robert E. Claypoole CEO
CXA Exchange
US09075A1088 ISIN
United States Country
1,030 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.

Products and Services

Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:

  • Durolane: A treatment for knee osteoarthritis providing pain relief.
  • GELSYN-3: A series of injections for knee osteoarthritis pain management.
  • SUPARTZ: An injectable solution for knee osteoarthritis.
  • Stimrouter: A device aimed at treating chronic peripheral pain.

Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:

  • Bone Graft Substitutes: Products like Osteoamp, Exponent matrix, Purebone, Signafuse bone graft, Interfuse bone graft, Osteomatrix+ synthetic bone graft, designed to stimulate bone healing.
  • Ultrasonic Products: High-precision devices such as nexus ultrasonic surgical system, bonescalpel surgical solution, SonaStar, and SonicOne ultrasonic cleansing and debridement system for surgeries, including minimally invasive procedures.
  • Extractor: A tool for autologous cell and bone marrow extraction to aid in bone healing.
  • Reficio Bone Matrix: A novel bone graft substitute.

Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:

  • Exogen: A bone healing system.
  • L300 GO: A system designed to improve foot drop conditions caused by central nervous system disorders.
  • H200 Rehabilitation System: A solution to aid in regaining hand function.
  • Vector: A body weight support system for gait and balance training.
  • Bioness Integrated Therapy System: Offers comprehensive solutions for neurorehabilitation.

The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.

Contact Information

Address: 4721 Emperor Boulevard
Phone: 919 474 6700